• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

TABLE 53Mixed-treatment comparison – ADAS-cog at 21–26 weeks (mean change from baseline, all measurement populations): results

TechnologyVs placeboProbability most effective
Effect95% CIProbability more effective than placebo
Placebo0.000
Donepezil−2.431−3.174 to −1.7091.0000.107
Galantamine−2.986−3.591 to −2.4051.0000.885
Rivastigmine−1.978−2.630 to −1.3031.0000.009
Memantine

From: 3, Assessment of clinical effectiveness

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.